durvalumab与tremelimumab的组合未能在NSCLC研究中击败化疗

2019-08-22 Allan MedSci原创

阿斯利康近日宣布,与标准铂类化疗相比,Imfinzi(durvalumab)联合使用tremelimumab治疗初治IV期非小细胞肺癌(NSCLC)患者的III期NEPTUNE研究未能达到总生存期(OS)的主要终点。

阿斯利康近日宣布,与标准铂类化疗相比,Imfinzidurvalumab)联合使用tremelimumab治疗初治IV期非小细胞肺癌NSCLC)患者的IIINEPTUNE研究未能达到总生存期(OS)的主要终点。阿斯利康肿瘤研发执行副总裁JoséBaselga表示:我们将致力于对该试验的大量临床和生物标志物数据进行深入分析,以获得进一步的见解

该研究将患有IVNSCLC患者随机分配至抗PD-L1抗体Imfinzi联合抗-CTLA4单克隆抗体tremelimumab组和标准铂类化疗组。该公司指出,该试验是在全部人群中进行的,受试者包括非鳞状或鳞状组织学,以及全范围PD-L1表达水平的受试者。


原始出处:

http://www.firstwordpharma.com/node/1660756#axzz5xBxiqv3r

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1752257, encodeId=980d1e5225727, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Fri Aug 30 19:58:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796381, encodeId=74201e96381d2, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17791, encryptionId=9a1b1e7916c, topicName=TREM)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Oct 02 19:58:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912197, encodeId=697d191219e28, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jun 14 10:58:00 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353207, encodeId=0d99135320ec3, content=<a href='/topic/show?id=ba5c1e796cf' target=_blank style='color:#2F92EE;'>#Tremelimumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17796, encryptionId=ba5c1e796cf, topicName=Tremelimumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 23 23:58:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039708, encodeId=27d91039e0830, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu Aug 22 11:58:00 CST 2019, time=2019-08-22, status=1, ipAttribution=)]
    2019-08-30 tongyongming
  2. [GetPortalCommentsPageByObjectIdResponse(id=1752257, encodeId=980d1e5225727, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Fri Aug 30 19:58:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796381, encodeId=74201e96381d2, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17791, encryptionId=9a1b1e7916c, topicName=TREM)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Oct 02 19:58:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912197, encodeId=697d191219e28, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jun 14 10:58:00 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353207, encodeId=0d99135320ec3, content=<a href='/topic/show?id=ba5c1e796cf' target=_blank style='color:#2F92EE;'>#Tremelimumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17796, encryptionId=ba5c1e796cf, topicName=Tremelimumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 23 23:58:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039708, encodeId=27d91039e0830, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu Aug 22 11:58:00 CST 2019, time=2019-08-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1752257, encodeId=980d1e5225727, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Fri Aug 30 19:58:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796381, encodeId=74201e96381d2, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17791, encryptionId=9a1b1e7916c, topicName=TREM)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Oct 02 19:58:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912197, encodeId=697d191219e28, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jun 14 10:58:00 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353207, encodeId=0d99135320ec3, content=<a href='/topic/show?id=ba5c1e796cf' target=_blank style='color:#2F92EE;'>#Tremelimumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17796, encryptionId=ba5c1e796cf, topicName=Tremelimumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 23 23:58:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039708, encodeId=27d91039e0830, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu Aug 22 11:58:00 CST 2019, time=2019-08-22, status=1, ipAttribution=)]
    2020-06-14 snf701207
  4. [GetPortalCommentsPageByObjectIdResponse(id=1752257, encodeId=980d1e5225727, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Fri Aug 30 19:58:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796381, encodeId=74201e96381d2, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17791, encryptionId=9a1b1e7916c, topicName=TREM)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Oct 02 19:58:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912197, encodeId=697d191219e28, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jun 14 10:58:00 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353207, encodeId=0d99135320ec3, content=<a href='/topic/show?id=ba5c1e796cf' target=_blank style='color:#2F92EE;'>#Tremelimumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17796, encryptionId=ba5c1e796cf, topicName=Tremelimumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 23 23:58:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039708, encodeId=27d91039e0830, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu Aug 22 11:58:00 CST 2019, time=2019-08-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1752257, encodeId=980d1e5225727, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Fri Aug 30 19:58:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796381, encodeId=74201e96381d2, content=<a href='/topic/show?id=9a1b1e7916c' target=_blank style='color:#2F92EE;'>#TREM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17791, encryptionId=9a1b1e7916c, topicName=TREM)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Wed Oct 02 19:58:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912197, encodeId=697d191219e28, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Jun 14 10:58:00 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353207, encodeId=0d99135320ec3, content=<a href='/topic/show?id=ba5c1e796cf' target=_blank style='color:#2F92EE;'>#Tremelimumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17796, encryptionId=ba5c1e796cf, topicName=Tremelimumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 23 23:58:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039708, encodeId=27d91039e0830, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Thu Aug 22 11:58:00 CST 2019, time=2019-08-22, status=1, ipAttribution=)]
    2019-08-22 肿肿

    NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了

    0

相关资讯

MYSTIC研究:durvalumab与tremelimumab联用无法显著提高肺癌患者的生存率

阿斯利康近日宣布,在III期MYSTIC研究中,与标准铂类化疗相比,PD-L1抑制剂Imfinzi(durvalumab)作为单药疗法及与抗CTLA4抗体tremelimumab的联合使用未能显著提高初治IV期非小细胞肺癌(NSCLC)患者的总生存期(OS)。

Lancet respir med:Tremelimumab(抗CTLA4单克隆抗体)联合durvalumab(抗PD-L1单克隆抗体)用于间皮瘤的疗效和安全性

Tremelimumab,抗CTLA4单克隆抗体,最初单独用于间皮瘤患者活性良好,但不能提高DETERMINE研究中一线或二线化疗失败的患者的总体存活率(与安慰剂对比)。现研究人员对Tremelimumab联合durvalumab(抗PD-L1单克隆抗体),作为一线或二线疗法,用于恶性间皮瘤的疗效和安全性进行评估。研究人员开展一开放性、非随机的临床II期试验,招募不可手术切除的胸膜或腹膜间皮瘤,予

J Hepatol:Tremelimumab治疗晚期肝癌的可行性研究

Tremelimumab是一个完全的人类单克隆抗体,结合于活化的T淋巴细胞表面的CTLA-4。消融疗法已被证明可以诱导外周免疫反应,从而增强抗CTLA4治疗晚期HCC患者的疗效。 纳入HCC患者(Childs Pugh A/B7;巴塞罗那临床肝癌分期B/C; ECOG 0/1)。结合消融疗法使用tremelimumab治疗。在基线和放射学介入时,进行肿瘤活检。 研究纳入了32例患者,男